Statewide analysis of missed opportunities for human papillomavirus vaccination using vaccine registry data

被引:36
作者
Kepka, Deanna [1 ,2 ,4 ]
Spigarelli, Michael G.
Warner, Echo L. [1 ,2 ]
Yoneoka, Yukiko [3 ]
McConnell, Nancy [3 ]
Balch, Alfred H. [4 ]
机构
[1] Univ Utah, Coll Nursing, 10 S 2000 E, Salt Lake City, UT 84112 USA
[2] Huntsman Canc Inst, Canc Control & Populat Sci, 2000 Circle Hope,Room 4144, Salt Lake City, UT 84112 USA
[3] Utah Dept Hlth, Utah Statewide Immunizat Informat Syst, 288 N 1460 W, Salt Lake City, UT 84116 USA
[4] Univ Utah, Dept Pediat, Div Clin Pharmacol, 100 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA
来源
PAPILLOMAVIRUS RESEARCH | 2016年 / 2卷
基金
美国国家卫生研究院;
关键词
HPV vaccine; Adolescent; Preventive medicine; Demographic factors; Registries;
D O I
10.1016/j.pvr.2016.06.002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Human papillomavirus (HPV) vaccine 3-dose completion rates among adolescent females in the US are low. Missed opportunities impede HPV vaccination coverage. Methods: A population-based secondary data analysis of de-identified vaccination and demographic data from the Utah Statewide Immunization Information System (USIIS) was conducted. Records were included from 25,866 females ages 11-26 years at any time during 2008-2012 who received at least one of the following adolescent vaccinations documented in the USIIS: Tdap (Tetanus, Diphtheria, Pertussis), meningococcal, and/or influenza. A missed opportunity for HPV vaccination was defined as a clinical encounter where the patient received at least one adolescent vaccination, but not a HPV vaccine. Results: Of 47,665 eligible visits, there were 20,911 missed opportunities (43.87%). Age group, race/ethnicity, and rurality were significantly associated with missed opportunity (p < 0.0001). In a multi variable mixed-effects logistic regression model that included ethnicity, location and age, as fixed effects and subject as a random effect, Hispanics were less likely to have a missed opportunity than whites OR 0.59 (95% CI: 0.52-0.66), small rural more likely to have a missed opportunity than urban youth OR 1.8 (95% CI: 1.5-2.2), and preteens more likely than teens OR 2.4 (95% CI: 2.2-2.7). Conclusion: Missed clinical opportunities are a significant barrier to HPV vaccination among female adolescents. Interventions targeted at providers who serve patient groups with the highest missed opportunities are needed to achieve adequate protection from HPV-associated illnesses. Impact: This is one of the first studies to utilize state immunization information system data to assess missed opportunities for HPV vaccination. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:128 / 132
页数:5
相关论文
共 50 条
  • [31] A Multilevel Analysis of School-Level Human Papillomavirus Vaccination Coverage in Virginia
    Mcnally, Kimberly
    Weinstein, Ali
    Lindley, Lisa
    Wallin, Robin
    Roess, Amira
    JOURNAL OF SCHOOL NURSING, 2023,
  • [32] National patterns in human papillomavirus vaccination An analysis of the national survey of family growth
    Sadigh, Gelareh
    Dempsey, Amanda F.
    Ruffin, Mack T.
    Resnicow, Ken
    Carlos, Ruth C.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (02)
  • [33] Applying Multiple Data Collection Tools to Quantify Human Papillomavirus Vaccine Communication on Twitter
    Massey, Philip M.
    Leader, Amy
    Yom-Tov, Elad
    Budenz, Alexandra
    Fisher, Kara
    Klassen, Ann C.
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2016, 18 (12)
  • [34] Understanding Human Papillomavirus Vaccination Intentions: Comparative Utility of the Theory of Reasoned Action and the Theory of Planned Behavior in Vaccine Target Age Women and Men
    Fisher, William A.
    Kohut, Taylor
    Salisbury, Claire M. A.
    Salvadori, Marina I.
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 (10) : 2455 - 2464
  • [35] Human Papillomavirus Vaccine Interventions in the US: A Systematic Review and Meta-analysis
    Rodriguez, Ana M.
    Do, Thuy Quynh N.
    Goodman, Michael
    Schmeler, Kathleen M.
    Kaul, Sapna
    Kuo, Yong-Fang
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2019, 56 (04) : 591 - 602
  • [36] Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study
    Willows, Karla
    Bozat-Emre, Songul
    Righolt, Christiaan H.
    Kliewer, Erich V.
    Mahmud, Salaheddin M.
    SEXUALLY TRANSMITTED DISEASES, 2018, 45 (04) : 254 - 259
  • [37] Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data
    Ali, Hammad
    McManus, Hamish
    O'Connor, Catherine C.
    Callander, Denton
    Kong, Marlene
    Graham, Simon
    Saulo, Dina
    Fairley, Christopher K.
    Regan, David G.
    Grulich, Andrew
    Low, Nicola
    Guy, Rebecca J.
    Donovan, Basil
    MEDICAL JOURNAL OF AUSTRALIA, 2017, 206 (05) : 204 - +
  • [38] Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators
    Spayne, Jacqueline
    Hesketh, Therese
    BMJ OPEN, 2021, 11 (09):
  • [39] Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
    Kim, Jane J.
    Goldie, Sue J.
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 909
  • [40] Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials
    Whitworth, Hilary S.
    Mounier-Jack, Sandra
    Choi, Edward M.
    Gallagher, Katherine E.
    Howard, Natasha
    Kelly, Helen
    Mbwanji, Gladys
    Kreimer, Aimee R.
    Basu, Partha
    Barnabas, Ruanne
    Drolet, Melanie
    Brisson, Marc
    Watson -Jones, Deborah
    VACCINE: X, 2024, 19